Entropy Technologies LP Buys New Holdings in Haleon plc (NYSE:HLN)

Entropy Technologies LP purchased a new position in Haleon plc (NYSE:HLN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 79,801 shares of the company’s stock, valued at approximately $761,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HLN. Lake Street Advisors Group LLC increased its stake in shares of Haleon by 5.4% in the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after buying an additional 1,143 shares during the period. Synovus Financial Corp grew its holdings in Haleon by 0.8% in the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after acquiring an additional 1,216 shares during the last quarter. Greenleaf Trust increased its position in shares of Haleon by 8.4% in the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock valued at $164,000 after acquiring an additional 1,333 shares during the period. Baron Wealth Management LLC increased its position in shares of Haleon by 4.3% in the fourth quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the period. Finally, Peapack Gladstone Financial Corp raised its stake in shares of Haleon by 3.2% during the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after acquiring an additional 1,390 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Up 1.7 %

Shares of HLN opened at $9.85 on Wednesday. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The firm has a market capitalization of $44.57 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 2.70 and a beta of 0.28. The firm’s 50-day moving average price is $9.53 and its 200-day moving average price is $9.79. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Wall Street Analysts Forecast Growth

HLN has been the topic of several recent analyst reports. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Haleon presently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.